enGene Therapeutics (ENGNW) Stock Price, News & Analysis
Company Description
enGene Therapeutics (NASDAQ: ENGNW) is classified in the Biological Products, (no Diagnostic Substances) sector.
ENGNW has declined 28.0% over the past year. Shares last traded at $0.5038.
For FY2025, enGene Therapeutics reported net income of -$117.3M and diluted earnings per share of $2.29.
This page collects what Stock Titan holds for ENGNW, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
enGene Therapeutics (ENGNW) stock last closed at $0.5038. Over the past 12 months, the stock has lost 28.0%.
ENGNW Rankings
Latest News
enGene Therapeutics has 2 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 1 with negative movement. Key topics include management. View all ENGNW news →
SEC Filings
enGene Therapeutics has filed 5 recent SEC filings, including 2 Form 3, 2 Form 8-K, 1 Form SCHEDULE 13G. The most recent filing was submitted on July 22, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ENGNW SEC filings →
Financial Highlights
operating income reached -$123.2M, and net income was -$117.3M. Diluted earnings per share stood at $2.29. The company generated -$99.2M in operating cash flow. With a current ratio of 11.75, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in enGene Therapeutics (ENGNW) currently stands at 77.0 thousand shares, up 4.1% from the previous reporting period. Since August 2025, short interest has increased by 62.6%. With 102.2 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for enGene Therapeutics (ENGNW) currently stands at 102.2 days, up 1919.4% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 95.8% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 102.2 days.
ENGNW Company Profile & Sector Positioning
enGene Therapeutics (ENGNW) operates in the Biological Products, (no Diagnostic Substances) sector and is listed on the NASDAQ.
Investors comparing ENGNW often look at related companies in the same sector, including Aspire Biopharma Holdings Inc (ASBPW), Biocardia (BCDAW), Briacell Therapeutics Corp (BCTXW), Briacell Therapeutics Corp (BCTXZ), and Celularity Inc (CELUW). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ENGNW's relative position within its industry.